For anyone holding the stock or thinking about it before the August earnings, Schott’s call is worth a closer look.<\/p>\n
JPMorgan raises its Eli Lilly price target to $1,400<\/h2>\n
JPMorgan analyst Chris Schott lifted his price target on Eli Lilly to $1,400 from $1,300<\/strong>, keeping an Overweight<\/strong> rating on the shares, Yahoo Finance reported.<\/p>\n The target sits well above the roughly $1,305<\/strong> Wall Street 12-month consensus, and it landed the same day LLY touched a fresh 52-week high<\/strong>.<\/p>\n More Healthcare Stocks:<\/strong><\/p>\n Schott called Lilly his top pick<\/strong> and pointed to two engines: the international expansion of Mounjaro<\/strong> and steady U.S. demand for Zepbound<\/strong>.<\/p>\n For Lilly’s coming quarter, he estimated total sales of about $20.7 billion<\/strong>, roughly $300 million<\/strong> above consensus, CNBC reported.<\/p>\n An Overweight rating means the analyst expects the stock to outperform its peers. The $1,400 target is where he thinks shares could trade by year-end.<\/p>\n Tom Werner / Getty Images<\/p>\n<\/figcaption><\/figure>\n To understand the target, it is important to see how dominant Lilly’s obesity franchise<\/strong> has become.<\/p>\n According to Lilly’s release, in the first quarter <\/strong>of 2026, revenue<\/strong>jumped<\/strong>55.5% to $19.8 billion<\/strong>. The rise was mostly driven by higher demand for Mounjaro and Zepbound.\u00a0<\/p>\n Those are the numbers behind Schott’s confidence.\u00a0<\/p>\n Demand growth<\/strong> has more than offset the lower prices Lilly agreed to in the U.S., which is exactly what its management said would happen.<\/p>\n The timing of the upgrade is not an accident.<\/p>\n On July 1<\/strong>, Medicare’s new GLP-1 Bridge <\/strong>program made Zepbound and the oral pill Foundayo available to eligible patients<\/strong> for as little as $50 a month<\/strong>, The Motley Fool noted.<\/p>\n Related: Eli Lilly makes surprising retreat from major market<\/strong><\/p>\n With an estimated 20 million Medicare patients<\/strong> potentially qualifying for obesity drugs, some analysts think the $1,400 target could be conservative.<\/p>\n Cheaper access usually means more prescriptions, and more prescriptions push up the sales that Wall Street is already counting on.<\/p>\n Beyond its current bestsellers, Schott pointed to Lilly’s deep pipeline of new drugs<\/strong>.<\/p>\n These new drugs include the oral GLP-1 candidate orforglipron<\/strong>, sold as Foundayo, and the triple-agonist retatrutide<\/strong>. <\/p>\n Together, the two new drugs target a market Schott values at over<\/strong>$200 billion<\/strong>.<\/p>\n Competitor setbacks have also helped Lilly\u2019s rise.\u00a0<\/p>\n Weak trial results<\/strong> from smaller rivals have reinforced how hard Lilly’s franchise is to challenge, which analysts describe as a wide competitive moat<\/strong>.<\/p>\n A moat, in investing terms, is a durable advantage that keeps competitors from eating into a company’s profits.<\/p>\n The rally has been steep. Here’s how the stock has performed against the market:<\/p>\n Lilly’s market value now sits near $1.16 trillion<\/strong>, with a price-to-earnings ratio<\/strong> around 44<\/strong>, The Motley Fool reports.<\/p>\n That high valuation means investors are already paying for a lot of good news.<\/p>\n The next real test comes on August 5<\/strong>, when Lilly reports second-quarter results<\/strong>.<\/p>\n Schott expects the company to meet or beat<\/strong> the high end of its estimate, but a high bar cuts both ways for a stock trading at record levels.<\/p>\n None of these is guaranteed, and a single disappointing quarter can hit the stock hard.<\/p>\n Anyone weighing LLY should size the position to their own risk tolerance and remember that even strong companies can see sharp pullbacks when expectations are this high.<\/p>\n Related: Banking giant massively resets Jazz Pharma stock price target<\/strong><\/p>\n #JPMorgan #resets #LLY #stock #target #drug #demand<\/p>\n","protected":false},"excerpt":{"rendered":" Eli Lilly (LLY) keeps setting records, and Wall Street\u2019s rating of its stock keeps increasing as well.\u00a0 On Tuesday, one of JPMorgan\u2019s most closely watched healthcare stock analysts, Chris Schott,… <\/p>\n","protected":false},"author":1,"featured_media":11288,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[246],"tags":[734,6494,1194,12868,481,91,1196],"class_list":["post-11287","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-popular","tag-demand","tag-drug","tag-jpmorgan","tag-lly","tag-resets","tag-stock","tag-target"],"_links":{"self":[{"href":"https:\/\/www.fintechpulse8.com\/index.php?rest_route=\/wp\/v2\/posts\/11287","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fintechpulse8.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fintechpulse8.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fintechpulse8.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fintechpulse8.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11287"}],"version-history":[{"count":0,"href":"https:\/\/www.fintechpulse8.com\/index.php?rest_route=\/wp\/v2\/posts\/11287\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fintechpulse8.com\/index.php?rest_route=\/wp\/v2\/media\/11288"}],"wp:attachment":[{"href":"https:\/\/www.fintechpulse8.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11287"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fintechpulse8.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11287"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fintechpulse8.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11287"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n
![](\"https:\/\/www.thestreet.com\/.image\/NDA6MDAwMDAwMDAzMTA2MDUy\/photo-3106052.jpg?profile=rss\")
Why Mounjaro and Zepbound keep driving Eli Lilly’s growth<\/h2>\n
What the franchise delivered last quarter<\/h3>\n
\n
How the new Medicare obesity program could widen Lilly’s lead<\/h2>\n
Eli Lilly’s pipeline and competitive moat in the obesity market<\/h2>\n
How Eli Lilly stock has performed against the market<\/h2>\n
LLY share-price snapshot<\/h3>\n
\n
What Eli Lilly investors should watch before August earnings<\/h2>\n
Key things that still need to go right<\/h3>\n
\n